Basilea gibt Abschluss der Patientenrekrutierung für Phase-1-Studie mit oralem BAL101553 bei Hirntumoren bekannt

NEXT STORY
New Data From Aslan’s Study of Varlitinib in China Accepted as Late-Breaking Oral Presentation at 2019 CSCO Annual Meeting
PREV STORY
Press release Biocartis NV: Invitation to the Special Shareholders’ Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Precision Therapeutics Signs Definitive Merger Agreement with Helomics Holding Corporation

MINNEAPOLIS, June 28, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the ...

author_avatar
NASDAQ Market News

Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer

Company strengthens management team with biopharmaceutical veteran bringing extensive commercial experience in life-threatening rare ...

author_avatar
NASDAQ Market News

Teladoc Announces Pricing of Sale of Shares of Common Stock

PURCHASE, NY, Nov. 29, 2017 (GLOBE NEWSWIRE) -- Teladoc, Inc. (NYSE:TDOC) (“Teladoc”) today announced the ...

author_avatar
NASDAQ Market News